Belgium continues to play an important role in the European regulatory landscape for medical devices, with a strong focus on compliance, safety monitoring, and alignment with European regulatory frameworks. The country’s national regulator, the Federal Agency for Medicines and Health Products (FAMHP), oversees the regulation of medicines and medical devices placed on the Belgian market. As the European Union continues to implement the European Union Medical Device Regulation

End of Transition Period for Clinical Trials FAHMP reminds all stakeholders, that starting from 31 January 2025 , all clinical trials...